DK1373259T3 - Pyridazinonaldosereduktaseinhibitorer - Google Patents

Pyridazinonaldosereduktaseinhibitorer

Info

Publication number: DK1373259T3
Authority: DK; Denmark
Prior art keywords: pyridazinonal; reductase inhibitors; dose; dose reductase; inhibitors
Prior art date: 2001-03-30

Application number

DK02716247T

Other languages

Danish (da)

English (en)

Inventor

Banavara Lakshman Mylari

Original Assignee

Pfizer Prod Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-03-30

Filing date

2002-01-31

Publication date

2005-03-29

2002-01-31 Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc

2005-03-29 Application granted granted Critical

2005-03-29 Publication of DK1373259T3 publication Critical patent/DK1373259T3/da

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Diabetes (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Hematology (AREA)
Cardiology (AREA)
Vascular Medicine (AREA)
Urology & Nephrology (AREA)
Heart & Thoracic Surgery (AREA)
Emergency Medicine (AREA)
Endocrinology (AREA)
Obesity (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Plural Heterocyclic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

DK02716247T 2001-03-30 2002-01-31 Pyridazinonaldosereduktaseinhibitorer DK1373259T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US28005101P	2001-03-30	2001-03-30
PCT/IB2002/000320 WO2002079198A1 (en)	2001-03-30	2002-01-31	Pyridazinone aldose reductase inhibitors

Publications (1)

Publication Number	Publication Date
DK1373259T3 true DK1373259T3 (da)	2005-03-29

Family

ID=23071435

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
DK02716247T DK1373259T3 (da)	2001-03-30	2002-01-31	Pyridazinonaldosereduktaseinhibitorer
DK04023149T DK1491540T3 (da)	2001-03-30	2002-01-31	Intermediater, der er anvendelige til syntese af pyridazinon-aldosereduktase inhibitorer

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
DK04023149T DK1491540T3 (da)	2001-03-30	2002-01-31	Intermediater, der er anvendelige til syntese af pyridazinon-aldosereduktase inhibitorer

Country Status (44)

Country	Link
US (2)	US6579879B2 (ja)
EP (3)	EP1491541B1 (ja)
JP (1)	JP2004528319A (ja)
KR (1)	KR100586138B1 (ja)
CN (1)	CN1215067C (ja)
AP (1)	AP2002002461A0 (ja)
AR (1)	AR035798A1 (ja)
AT (3)	ATE286049T1 (ja)
AU (1)	AU2002226634B2 (ja)
BG (1)	BG108179A (ja)
BR (1)	BR0208571A (ja)
CA (1)	CA2442476A1 (ja)
CZ (1)	CZ20032563A3 (ja)
DE (3)	DE60202452C5 (ja)
DK (2)	DK1373259T3 (ja)
EA (1)	EA006023B1 (ja)
EC (1)	ECSP034671A (ja)
EE (1)	EE200300470A (ja)
ES (2)	ES2274369T3 (ja)
GE (1)	GEP20053675B (ja)
HK (1)	HK1061678A1 (ja)
HR (1)	HRP20030752A2 (ja)
HU (1)	HUP0303644A3 (ja)
IL (1)	IL156462A0 (ja)
IS (3)	IS2205B (ja)
MA (1)	MA27003A1 (ja)
MX (1)	MXPA03008850A (ja)
MY (1)	MY134304A (ja)
NO (1)	NO20034345L (ja)
NZ (1)	NZ528406A (ja)
OA (1)	OA12453A (ja)
PA (1)	PA8541801A1 (ja)
PE (1)	PE20030007A1 (ja)
PL (1)	PL365294A1 (ja)
PT (2)	PT1491540E (ja)
SI (1)	SI1373259T1 (ja)
SK (1)	SK11852003A3 (ja)
TN (1)	TNSN02037A1 (ja)
TW (1)	TWI245762B (ja)
UA (1)	UA73236C2 (ja)
UY (1)	UY27237A1 (ja)
WO (1)	WO2002079198A1 (ja)
YU (1)	YU71403A (ja)
ZA (1)	ZA200304671B (ja)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
HU228426B1 (hu)	1996-07-24	2013-03-28	Warner Lambert Co	Izobutil-gaba és származékai alkalmazása fájdalom kezelésére alkalmas gyógyszer elõállítására
EP1236720B1 (en) *	2001-02-28	2005-06-15	Pfizer Products Inc.	Sulfonyl pyridazinone compounds useful as aldose reductase inhibitors
PT1491540E (pt) *	2001-03-30	2007-01-31	Pfizer Prod Inc	Intermediários úteis na síntese de inibidores piridazinona de aldose reductase
AU761191B2 (en) *	2001-05-24	2003-05-29	Pfizer Products Inc.	Therapies for tissue damage resulting from ischemia
PL371258A1 (en)	2002-01-09	2005-06-13	Pfizer Products Inc.	Process and intermediates for pyridazinone antidiabetic agents
US7419981B2 (en) *	2002-08-15	2008-09-02	Pfizer Inc.	Synergistic combinations of an alpha-2-delta ligand and a cGMP phosphodieterse 5 inhibitor
US20040092522A1 (en) *	2002-08-15	2004-05-13	Field Mark John	Synergistic combinations
US6872833B2 (en) *	2003-04-14	2005-03-29	Hoffmann-La Roche Inc.	Adenosine receptor ligands
US8017634B2 (en)	2003-12-29	2011-09-13	President And Fellows Of Harvard College	Compositions for treating obesity and insulin resistance disorders
US7262318B2 (en) *	2004-03-10	2007-08-28	Pfizer, Inc.	Substituted heteroaryl- and phenylsulfamoyl compounds
PE20060272A1 (es)	2004-05-24	2006-05-22	Glaxo Group Ltd	(2r,3r,4s,5r,2'r,3'r,4's,5's)-2,2'-{trans-1,4-ciclohexanodiilbis-[imino(2-{[2-(1-metil-1h-imidazol-4-il)etil]amino}-9h-purin-6,9-diil)]}bis[5-(2-etil-2h-tetrazol-5-il)tetrahidro-3,4-furanodiol] como agonista a2a
DE602005025755D1 (de)	2004-06-04	2011-02-17	Teva Pharma	Irbesartan enthaltende pharmazeutische zusammensetzung
US20050288340A1 (en) *	2004-06-29	2005-12-29	Pfizer Inc	Substituted heteroaryl- and phenylsulfamoyl compounds
EP1769088A2 (en) *	2004-06-30	2007-04-04	Whitehead Institute For Biomedical Research	Novel methods for high-throughput genome-wide location analysis
GB0514809D0 (en)	2005-07-19	2005-08-24	Glaxo Group Ltd	Compounds
US7741317B2 (en)	2005-10-21	2010-06-22	Bristol-Myers Squibb Company	LXR modulators
US7888376B2 (en)	2005-11-23	2011-02-15	Bristol-Myers Squibb Company	Heterocyclic CETP inhibitors
RU2008127501A (ru) *	2006-01-13	2010-02-20	Вайет (Us)	Сульфонилзамещенные 1н-индолы в качастве лигандов 5-гидрокситриптаминовых рецепторов
ES2379661T3 (es)	2006-06-27	2012-04-30	Takeda Pharmaceutical Company Limited	Compuestos cíclicos condensados
JP5498168B2 (ja)	2006-12-01	2014-05-21	ブリストル−マイヤーズスクイブカンパニー	アテローム性動脈硬化および循環器疾患の治療のためのｃｅｔｐ阻害剤としてのｎ−（（３−ベンジル）−２，２−（ビス−フェニル）−プロパン−１−アミン誘導体
US8173645B2 (en) *	2007-03-21	2012-05-08	Takeda San Diego, Inc.	Glucokinase activators
JP2010043063A (ja)	2008-05-09	2010-02-25	Agency For Science Technology & Research	川崎病の診断及び治療
AU2010328186B2 (en)	2009-12-08	2014-12-18	Case Western Reserve University	Compounds and methods of treating ocular disorders
US8916563B2 (en)	2010-07-16	2014-12-23	The Trustees Of Columbia University In The City Of New York	Aldose reductase inhibitors and uses thereof
KR20140091522A (ko) *	2011-09-15	2014-07-21	타이페이 메디컬 유니이버시티	심부전증 또는 신경 손상을 치료하기 위한 인돌릴 및 인돌리닐 하이드록사메이트의 용도
US9339542B2 (en) *	2013-04-16	2016-05-17	John L Couvaras	Hypertension reducing composition
AU2014255381A1 (en)	2013-04-17	2015-10-08	Pfizer Inc.	N-piperidin-3-ylbenzamide derivatives for treating cardiovascular diseases
CN103739547B (zh) *	2014-01-03	2015-09-02	沈阳药科大学	2-[6-甲氧基-3-(2,3-二氯苯基)甲基-4-氧代-1,4-二氢-1(4h)-喹啉基]乙酸的合成方法
WO2016055901A1 (en)	2014-10-08	2016-04-14	Pfizer Inc.	Substituted amide compounds
JP2018511616A (ja) *	2015-04-14	2018-04-26	ケースウエスタンリザーブユニバーシティ	短鎖デヒドロゲナーゼ活性を調節する組成物および方法
WO2017168174A1 (en)	2016-04-02	2017-10-05	N4 Pharma Uk Limited	New pharmaceutical forms of sildenafil
PL3757107T3 (pl)	2016-06-21	2024-03-18	The Trustees Of Columbia University In The City Of New York	Związki 4-okso-3,4-dihydrotieno[3,4-d]pirydazyny jako inhibitory reduktazy aldozy i sposoby ich użycia
WO2018002673A1 (en)	2016-07-01	2018-01-04	N4 Pharma Uk Limited	Novel formulations of angiotensin ii receptor antagonists
US10344002B2 (en)	2016-09-26	2019-07-09	Nusirt Sciences, Inc.	Compositions and methods for treating metabolic disorders
JP2020502070A (ja)	2016-11-30	2020-01-23	ケースウエスタンリザーブユニバーシティ	１５−ｐｇｄｈ阻害剤とコルチコステロイドおよび／またはｔｎｆ阻害剤との組み合わせならびにその使用
AU2018215678A1 (en)	2017-02-06	2019-08-22	Board Of Regents Of The University Of Texas System	Compositions and methods of modulating short-chain dehydrogenase activity
HRP20240840T1 (hr)	2017-07-28	2024-10-11	Applied Therapeutics, Inc	Pripravci i postupci za liječenje galaktozemije
JOP20210193A1 (ar)	2019-01-18	2023-01-30	Astrazeneca Ab	مثبطات pcsk9 وطرق استخدامها
BR112021021939A2 (pt)	2019-05-07	2022-02-22	Ucl Business Ltd	Tratamento e detecção de neuropatias herdadas e distúrbios associados
AU2020282757A1 (en)	2019-05-31	2021-12-23	Ikena Oncology, Inc.	TEAD inhibitors and uses thereof
AU2020282759A1 (en)	2019-05-31	2021-12-23	Ikena Oncology, Inc.	TEAD inhibitors and uses thereof
WO2022120353A1 (en) *	2020-12-02	2022-06-09	Ikena Oncology, Inc.	Tead inhibitors and uses thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IE47592B1 (en)	1977-12-29	1984-05-02	Ici Ltd	Enzyme inhibitory phthalazin-4-ylacetic acid derivatives, pharmaceutical compositions thereof,and process for their manufacture
US4939140A (en)	1985-11-07	1990-07-03	Pfizer Inc.	Heterocyclic oxophthalazinyl acetic acids
US4996204A (en)	1989-05-11	1991-02-26	Pfizer Inc.	Pyrido[2,3-d]pyridazinones as aldose reductase inhibitors
FR2647676A1 (fr)	1989-06-05	1990-12-07	Union Pharma Scient Appl	Nouveaux derives de pyridazinone, leurs procedes de preparation, medicaments les contenant, utiles notamment comme inhibiteurs de l'aldose reductase
WO1992009594A1 (en) *	1990-11-30	1992-06-11	Tsumura & Co.	Chromone derivative and aldose reductase inhibitor containing the same as active ingredient
JPH06500793A (ja)	1991-03-28	1994-01-27	フアイザー・インコーポレイテツド	ピリダジノン酢酸
US5834466A (en)	1994-12-22	1998-11-10	The Regents Of The University Of California	Method for protecting of heart by limiting metabolic and ionic abnormalities developed during ischemia, following ischemia or resulting from ischemia
TWI238064B (en)	1995-06-20	2005-08-21	Takeda Chemical Industries Ltd	A pharmaceutical composition for prophylaxis and treatment of diabetes
WO1999015523A1 (en) *	1997-09-24	1999-04-01	Orion Corporation	Bisethers of 1-oxa, aza and thianaphthalen-2-ones as phospholamban inhibitors
FR2822827B1 (fr) *	2001-03-28	2003-05-16	Sanofi Synthelabo	Nouveaux derives de n-(arylsulfonyl) beta-aminoacides comportant un groupe aminomethyle substitue, leur procede de preparation et les compositions pharmaceutiques en contenant
PT1491540E (pt) *	2001-03-30	2007-01-31	Pfizer Prod Inc	Intermediários úteis na síntese de inibidores piridazinona de aldose reductase
JP2004528344A (ja) *	2001-04-30	2004-09-16	ファイザー・プロダクツ・インク	アルドースレダクターゼ阻害薬とシクロオキシゲナーゼ−２阻害薬の併用
PL371258A1 (en) *	2002-01-09	2005-06-13	Pfizer Products Inc.	Process and intermediates for pyridazinone antidiabetic agents

2002
- 2002-01-31 PT PT04023149T patent/PT1491540E/pt unknown
- 2002-01-31 BR BR0208571-2A patent/BR0208571A/pt not_active IP Right Cessation
- 2002-01-31 SK SK1185-2003A patent/SK11852003A3/sk unknown
- 2002-01-31 JP JP2002577823A patent/JP2004528319A/ja active Pending
- 2002-01-31 AT AT02716247T patent/ATE286049T1/de active
- 2002-01-31 HU HU0303644A patent/HUP0303644A3/hu unknown
- 2002-01-31 EP EP04023150A patent/EP1491541B1/en not_active Expired - Lifetime
- 2002-01-31 EA EA200300673A patent/EA006023B1/ru not_active IP Right Cessation
- 2002-01-31 MX MXPA03008850A patent/MXPA03008850A/es active IP Right Grant
- 2002-01-31 OA OA1200300222A patent/OA12453A/en unknown
- 2002-01-31 ES ES04023149T patent/ES2274369T3/es not_active Expired - Lifetime
- 2002-01-31 AT AT04023149T patent/ATE348100T1/de not_active IP Right Cessation
- 2002-01-31 DK DK02716247T patent/DK1373259T3/da active
- 2002-01-31 SI SI200230071T patent/SI1373259T1/xx unknown
- 2002-01-31 CN CNB028076001A patent/CN1215067C/zh not_active Expired - Fee Related
- 2002-01-31 EP EP02716247A patent/EP1373259B1/en not_active Expired - Lifetime
- 2002-01-31 NZ NZ528406A patent/NZ528406A/en unknown
- 2002-01-31 EE EEP200300470A patent/EE200300470A/xx unknown
- 2002-01-31 EP EP04023149A patent/EP1491540B1/en not_active Expired - Lifetime
- 2002-01-31 DK DK04023149T patent/DK1491540T3/da active
- 2002-01-31 DE DE60202452T patent/DE60202452C5/de not_active Expired - Fee Related
- 2002-01-31 ES ES02716247T patent/ES2231681T3/es not_active Expired - Lifetime
- 2002-01-31 KR KR1020037012753A patent/KR100586138B1/ko not_active IP Right Cessation
- 2002-01-31 GE GE5314A patent/GEP20053675B/en unknown
- 2002-01-31 DE DE60216823T patent/DE60216823T2/de not_active Expired - Fee Related
- 2002-01-31 WO PCT/IB2002/000320 patent/WO2002079198A1/en active IP Right Grant
- 2002-01-31 IL IL15646202A patent/IL156462A0/xx unknown
- 2002-01-31 CA CA002442476A patent/CA2442476A1/en not_active Abandoned
- 2002-01-31 AT AT04023150T patent/ATE352551T1/de not_active IP Right Cessation
- 2002-01-31 UA UA2003098846A patent/UA73236C2/uk unknown
- 2002-01-31 PL PL02365294A patent/PL365294A1/xx not_active Application Discontinuation
- 2002-01-31 AU AU2002226634A patent/AU2002226634B2/en not_active Ceased
- 2002-01-31 YU YU71403A patent/YU71403A/sh unknown
- 2002-01-31 DE DE60217930T patent/DE60217930T2/de not_active Expired - Fee Related
- 2002-01-31 PT PT02716247T patent/PT1373259E/pt unknown
- 2002-03-21 US US10/104,664 patent/US6579879B2/en not_active Expired - Fee Related
- 2002-03-22 PA PA20028541801A patent/PA8541801A1/es unknown
- 2002-03-27 PE PE2002000246A patent/PE20030007A1/es not_active Application Discontinuation
- 2002-03-27 MY MYPI20021093A patent/MY134304A/en unknown
- 2002-03-27 UY UY27237A patent/UY27237A1/es not_active Application Discontinuation
- 2002-03-27 AR ARP020101134A patent/AR035798A1/es unknown
- 2002-03-28 AP APAP/P/2002/002461A patent/AP2002002461A0/en unknown
- 2002-03-29 TN TNTNSN02037A patent/TNSN02037A1/fr unknown
- 2002-03-29 TW TW091106386A patent/TWI245762B/zh not_active IP Right Cessation
- 2002-03-31 CZ CZ20032563A patent/CZ20032563A3/cs unknown
2003
- 2003-02-20 US US10/370,895 patent/US6849629B2/en not_active Expired - Fee Related
- 2003-06-16 IS IS6845A patent/IS2205B/is unknown
- 2003-06-17 ZA ZA200304671A patent/ZA200304671B/en unknown
- 2003-06-25 EC EC2003004671A patent/ECSP034671A/es unknown
- 2003-09-17 HR HR20030752A patent/HRP20030752A2/hr not_active Application Discontinuation
- 2003-09-17 MA MA27314A patent/MA27003A1/fr unknown
- 2003-09-17 BG BG108179A patent/BG108179A/xx unknown
- 2003-09-29 NO NO20034345A patent/NO20034345L/no unknown
2004
- 2004-06-24 HK HK04104538A patent/HK1061678A1/xx not_active IP Right Cessation
2006
- 2006-01-23 IS IS8251A patent/IS8251A/is unknown
- 2006-01-23 IS IS8250A patent/IS8250A/is unknown

Also Published As

Publication number	Publication date
DE60202452T2 (de)	2006-02-09
EP1373259B1 (en)	2004-12-29
IL156462A0 (en)	2004-01-04
DE60216823T2 (de)	2007-10-04
EA200300673A1 (ru)	2003-12-25
ZA200304671B (en)	2004-06-25
UY27237A1 (es)	2002-12-31
IS2205B (is)	2007-02-15
PT1373259E (pt)	2005-03-31
AU2002226634B2 (en)	2007-01-25
ES2274369T3 (es)	2007-05-16
EP1491541A1 (en)	2004-12-29
CZ20032563A3 (cs)	2004-05-12
US20020143017A1 (en)	2002-10-03
OA12453A (en)	2006-05-24
NO20034345D0 (no)	2003-09-29
DE60216823D1 (de)	2007-01-25
KR20030088484A (ko)	2003-11-19
UA73236C2 (en)	2005-06-15
EP1491540B1 (en)	2006-12-13
US20030162784A1 (en)	2003-08-28
YU71403A (sh)	2006-05-25
NZ528406A (en)	2004-03-26
IS6845A (is)	2003-06-16
AR035798A1 (es)	2004-07-14
WO2002079198A1 (en)	2002-10-10
EP1491540A1 (en)	2004-12-29
MY134304A (en)	2007-12-31
US6579879B2 (en)	2003-06-17
PA8541801A1 (es)	2002-10-28
DE60217930D1 (de)	2007-03-15
TNSN02037A1 (fr)	2005-12-23
KR100586138B1 (ko)	2006-06-07
NO20034345L (no)	2003-09-29
JP2004528319A (ja)	2004-09-16
IS8250A (is)	2006-01-23
PL365294A1 (en)	2004-12-27
ATE286049T1 (de)	2005-01-15
US6849629B2 (en)	2005-02-01
HUP0303644A2 (hu)	2004-03-01
BR0208571A (pt)	2004-03-23
CA2442476A1 (en)	2002-10-10
EA006023B1 (ru)	2005-08-25
AP2002002461A0 (en)	2002-06-30
DE60202452C5 (de)	2006-11-23
DE60202452D1 (de)	2005-02-03
HUP0303644A3 (en)	2008-06-30
DE60217930T2 (de)	2007-10-18
ATE352551T1 (de)	2007-02-15
ECSP034671A (es)	2003-08-29
EP1373259A1 (en)	2004-01-02
EP1491541B1 (en)	2007-01-24
TWI245762B (en)	2005-12-21
CN1215067C (zh)	2005-08-17
EE200300470A (et)	2004-02-16
MA27003A1 (fr)	2004-12-20
PE20030007A1 (es)	2003-01-28
SK11852003A3 (sk)	2004-07-07
MXPA03008850A (es)	2003-12-04
SI1373259T1 (en)	2005-04-30
ES2231681T3 (es)	2005-05-16
GEP20053675B (en)	2005-11-25
PT1491540E (pt)	2007-01-31
BG108179A (en)	2004-09-30
CN1500087A (zh)	2004-05-26
ATE348100T1 (de)	2007-01-15
DK1491540T3 (da)	2007-03-26
HK1061678A1 (en)	2004-09-30
HRP20030752A2 (en)	2005-06-30
IS8251A (is)	2006-01-23

Publication	Publication Date	Title
DE60202452D1 (de)	2005-02-03	Pyridazinonaldose reductase inhibitoren
CY2015028I2 (el)	2016-07-27	Ενας αναστολεας ν-ακυλοσφιγγοσινο γλυκοζυλοτρανσφερασης
DE60234125D1 (de)	2009-12-03	E inhibitoren
PT1370553E (pt)	2006-09-29	Inibidores de rhoquinase
DK1223918T3 (da)	2003-04-28	Farmaceutiske præparater omfattende en HMG-CoA-reductaseinhibitor
DE60218138D1 (de)	2007-03-29	Rho-kinase inhibitoren
NO20034044L (no)	2003-11-10	Metallproteinase-inhibitorer
ATE505471T1 (de)	2011-04-15	Azaindol-kinaseinhibitoren
ATE397925T1 (de)	2008-07-15	Cis-imidazoline als mdm2-hemmer
IS7138A (is)	2004-01-30	Alkýn-arýl fosfódíesterasa-4 hindrar
EE200300439A (et)	2003-12-15	Metalloproteinaasi inhibiitorid
DK1560584T3 (da)	2009-05-18	Fab I inhibitorer
DE50303193D1 (de)	2006-06-08	Übertrager
NO20034032D0 (no)	2003-09-11	Metallproteinase-inhibitorer
DK1272488T3 (da)	2006-07-17	Tri-aryl-substitueret ethan-PDE4-inhibitorer
DE60110029D1 (de)	2005-05-19	Papierzuführwalze
NO20013535L (no)	2002-09-09	Nöytrofil-funksjons-inhibitorer
ITMI20010954A0 (it)	2001-05-10	Procedimento di iodurazione
DE60229669D1 (de)	2008-12-11	X-2 inhibitoren
ATE354561T1 (de)	2007-03-15	Substituierte 1-aryl-but-3-enylamin- und 1-aryl- but-2-enylaminverbindungen
DE50115802D1 (de)	2011-04-07	Dafür
SE0100694D0 (sv)	2001-02-28	DHFR inhibitors
ITMI20011624A0 (it)	2001-07-26	Timpano di tompagnatura
FI5322U1 (fi)	2002-04-30	Kulmaosa
SE0102987D0 (sv)	2001-09-09	Länsa